宏力医疗管理(09906)发布2025年中期业绩，收入3.47亿元(人民币，下同)，同比减少16.5%;股东应占亏 损67.3万元，上年同期股东应占溢利2004.2万元，同比盈转亏。 ...

天眼查显示，近日，赣州颐和医疗管理有限公司成立，法定代表人为张淳，注册资本200万人民币，由 于都安颐和精神专科医院有限公司全资持股。 序号股东名称持股比例1于都安颐和精神专科医院有限公司100% 经营范围含医院管理，远程健康管理服务，健康咨询服务（不含诊疗服务），护理机构服务（不含医疗 服务），第二类医疗设备租赁，第一类医疗设备租赁，卫生用品和一次性使用医疗用品销售，特种劳动 防护用品销售，医护人员防护用品批发，消毒剂销售（不含危险化学品），技术服务、技术开发、技术 咨询、技术交流、技术转让、技术推广，国内贸易代理（除依法须经批准的项目外，凭营业执照依法自 主开展经营活动） 企业名称赣州颐和医疗管理有限公司法定代表人张淳注册资本200万人民币国标行业卫生和社会工作> 卫生>医院地址江西省赣州市章贡区新赣州大道18号阳明国际中心3号楼17-17#办公企业类型有限责任公 司(自然人投资或控股的法人独资)营业期限2025-8-22至无固定期限登记机关章贡区市场监督管理局 来源：金融界 ...

证券代码：000788 证券简称：北大医药 公告编号：2025-058 北大医药股份有限公司 关于同意公司配合参股公司减资 及拟启动清算解散工作的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 一届董事会第十三次会议审议通过了《关于同意公司配合参股公司减资及拟启动 清算解散工作的议案》。受市场环境等多方面因素影响，公司参股公司北京北大 医疗肿瘤医院管理有限公司（以下简称"肿瘤医院管理公司"）因经营存在严重 困难，故申请拟先将其注册资本由 30,000 万元减少至 10,000 万元（以下简称"本 次减资"）后再启动清算解散工作。公司基于整体战略规划，为优化投资布局， 降低经营风险，更好维护公司及包括中小股东在内的全体股东利益，提请董事会 同意公司配合参股公司肿瘤医院管理公司本次减资及后续拟启动的清算解散工 作。具体情况如下： 一、基本情况概述 肿瘤医院管理公司为公司参股公司，注册资本为 30,000 万元人民币，实缴 资本为 10,000 万元人民币。其中，公司出资 4, ...

Core Viewpoint - Recently, Ji Bo Medical has undergone a business scope change, shifting from a focus on medical management and investment in healthcare projects to a broader range of services including research, consulting, and management activities [1] Group 1: Business Scope Change - The business scope has changed from managing medical and outpatient departments, medical research and development, and investment in dental and other medical projects to general projects such as medical research and development, hospital management, and enterprise management [1] - New services include investment activities with self-owned funds, real estate registration agency services, information consulting services (excluding licensed information consulting), and social economic consulting services [1] - The company can now engage in leasing services (excluding licensed leasing), conference and exhibition services, business training (excluding educational training requiring permits), and technical services including development, consulting, and transfer [1]

Core Viewpoint - The company, Innovation Medical Management Co., Ltd., reported a slight decrease in revenue but a significant improvement in net profit compared to the previous year, indicating a potential recovery in financial performance [1]. Financial Performance - Revenue for the reporting period was approximately ¥401.53 million, a decrease of 1.60% compared to ¥408.04 million in the same period last year [1]. - The net profit attributable to shareholders was a loss of ¥11.36 million, which is an improvement of 29.12% from a loss of ¥16.03 million in the previous year [1]. - The net profit after deducting non-recurring gains and losses was a loss of ¥12.88 million, showing a 22.42% improvement from a loss of ¥16.61 million last year [1]. - The net cash flow from operating activities was ¥83.72 million, a significant increase of 2,578.88% compared to a negative cash flow of ¥3.38 million in the previous year [1]. - Basic and diluted earnings per share improved to -¥0.03 from -¥0.04, reflecting a 25.00% increase [1]. Asset and Equity Position - Total assets at the end of the reporting period were approximately ¥2.15 billion, a decrease of 2.25% from ¥2.20 billion at the end of the previous year [1]. - The net assets attributable to shareholders were approximately ¥1.76 billion [1]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 82,043 [2]. - The largest shareholder, Chen Xiaying, holds 17.59% of the shares, while other significant shareholders include Chen Haijun with 5.04% and Shanghai Guanghuan Technology Co., Ltd. with 4.97% [2]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [2].

Core Viewpoint - Neusoft Ruixin Group (09616) anticipates a decline of approximately 20%-30% in both profit attributable to shareholders and adjusted net profit for the six months ending June 30, 2025, compared to the same period in 2024 [1] Group 1: Financial Performance - The company expects profit attributable to shareholders to decrease by about 20%-30% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - Adjusted net profit is also projected to decline by approximately 20%-30% for the same period [1] Group 2: Reasons for Decline - The decline in profit is primarily attributed to increased costs and expenses due to the strategic transformation and upgrade of the business model, including the acquisition of Neusoft Health Management Co., Ltd. completed on May 31, 2024 [1] - Additional investments in other health-related businesses to promote strategic transformation and upgrade have contributed to the increased costs [1] - Delays in the delivery of educational technology products have led to reduced revenue from educational resource output, while market changes have resulted in decreased enrollment and revenue from continuing education services [1]

证券代码：002173 证券简称：创新医疗 公告编号：2025-047 创新医疗管理股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 （一）会议召开情况： （1）现场会议时间：2025年7月30日（星期三）14:00； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年7 月30日9:15—9:25，9:30—11:30，13:00—15:00；通过深圳证券交易所互联网 投票系统（http://wltp.cninfo.com.cn）投票时间为2025年7月30日9:15至15:00。 律、行政法规、部门规章、规范性文件及公司《章程》的有关规定。 （二）会议出席情况 出 席 本 次 股 东 会 的 股 东 及 股 东 代 理 人 共 639 人 ， 代 表 有 表 决 权 股 份 （1）出席现场会议的股东及股东代理人 出席本次股东会现场会议的股东及股东代表共 6 名，该等股东持有公司股份 （2）参加网络投票的股东 本次股东会通过网络投票系统进行有效表决的股东共计 633 人，代表有表决 权股份 4 ...

Core Viewpoint - The collaboration of 28 hospitals and universities in China to develop a textbook on medical management signifies a response to the current lack of educational resources in this field, aiming to enhance the quality of medical management education and practice [1][2]. Group 1: Textbook Development - The textbook titled "Medical Management" is initiated by the First Affiliated Hospital of Chongqing Medical University and Tsinghua University Hospital Management Research Institute, organized by the People's Medical Publishing House [1]. - The editorial board consists of experts from prestigious institutions such as Tsinghua University, Fudan University, and Huazhong University of Science and Technology, ensuring the authority and practicality of the textbook [1]. - The initiative addresses the shortage of undergraduate and graduate planning textbooks in medical management and the need for interdisciplinary resources in the context of smart hospital construction [1]. Group 2: Educational Features - The textbook will incorporate a "fusion, balance, integration, and application" approach, combining knowledge from management, medicine, and law [2]. - It aims to balance various methodologies, addressing both theoretical and practical aspects of medical management [2]. - The inclusion of a case library, exercise collection, and digital platform is intended to enhance the applicability of the teaching materials [2].

Company Formation - Tianjin Harbin Standard Medical Management Co., Ltd. has been established with a registered capital of 10 million RMB [1] - The legal representative of the company is Liu Dongmei, and it is wholly owned by Anhui Harbin Standard Medical Health Industry Co., Ltd. [1] Business Scope - The business scope includes hospital management, production of Class I medical devices, technical services, development, consulting, and sales of medical equipment [2] - The company is also involved in the production and retail of medical masks and protective supplies for healthcare personnel, as well as leasing of medical equipment [2] Company Details - The company is classified as a limited liability company (sole proprietorship) and is located in the Wuqing Development Zone, Tianjin [2] - The business registration is valid until July 22, 2025, with no fixed term thereafter [2]

Group 1 - The Hong Kong Hospital Authority has implemented information technology to streamline administrative processes, enhance procurement of medical instruments, and manage energy consumption, resulting in an estimated savings of at least 1 billion HKD over the past two years [1] - The procurement budget for medical instruments and maintenance in the 2023-24 fiscal year is projected to reach 5.7 billion HKD, with a focus on increasing competition among suppliers, including those from mainland China and overseas [1] - A cost assessment group has been established to negotiate with pharmaceutical companies, achieving a willingness from 70% of them to reduce prices, particularly for cancer treatment drugs, with an average reduction of up to 20% [1] Group 2 - The Hong Kong Hospital Authority has recently utilized artificial intelligence to generate medical and discharge reports, reducing paperwork time by 40% and workload by over 30%, while ensuring that all reports are reviewed by doctors before issuance [2] - An AI risk warning system has been implemented to predict patient risks and develop targeted treatment plans, improving treatment outcomes and reducing hospital stay durations [2] - In 2023, the Hong Kong Hospital Authority achieved a 7% reduction in energy consumption, surpassing the initial target of 5%, and aims to reduce electricity usage by approximately 20% by 2035 through innovative energy-saving technologies [2]